Bristol-Myers Squibb Co
Stocks making the biggest moves midday: 3M, Dexcom, Sweetgreen, Texas Roadhouse and more
Check out the companies making headlines in midday trading: 3M — The stock skyrocketed more than 18% to hit a 52-week high after the maker of office supplies and adhesives reported stronger-than-expected quarterly results. 3M posted second-quarter adjusted earnings of $1.93 per share, exceeding an LSEG estimate of $1.68 per share. Its revenue also came […]
Read More
Stocks making the biggest moves premarket: Coursera, WW International, DexCom, Deckers and more
Check out the companies making headlines before the bell. CrowdStrike — Shares of CrowdStrike were up nearly 2% after CEO George Kurtz said that more than 97% of Window sensors were back online after last week’s global IT outage. However, the stock is on pace for a 17% week-to-date decline. Semiconductor stocks — Nvidia , […]
Read More
Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs
The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, on Dec. 27, 2023. Adam Glanzman | Bloomberg | Getty Images Bristol Myers Squibb on Friday reported second-quarter earnings and revenue that topped expectations and raised its full-year guidance as the drugmaker moves to slash costs. The pharmaceutical giant raised its […]
Read More
Stock futures rise slightly as investors prepare for Fed’s preferred inflation gauge: Live updates
Traders work on the floor of the New York Stock Exchange (NYSE) as a picture of Vice President Kamala Harris is displayed on a television screen on July 22, 2024 in New York City. Spencer Platt | Getty Images Stock futures rose modestly on Thursday evening as the major averages head for weekly losses and […]
Read More
Healthy Returns: The first round of Medicare drug price negotiations is nearing an end
Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services building in Washington, D.C., on Oct. 6, 2022. Anna Moneymaker | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! The first round […]
Read More
The ‘Trump trade’ is on pause. Political uncertainty is now in the driver’s seat
It didn’t take long to remember what a second Donald Trump presidential term would mean for the stock market, did it? Unpredictability. Random attacks. No one safe. Mercurial positions. The only difference? Former Vice President Mike Pence meant nothing. He was supposed to mean nothing. Now the Republican candidate’s new running mate, Sen. JD Vance […]
Read More
Pfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline
Kena Betancur | Corbis News | Getty Images Pfizer had a “phenomenal” first quarter — and Wall Street took notice, CEO Albert Bourla told thousands of employees during a companywide town hall on May 2, according to a recording heard by CNBC. A day earlier, the pharmaceutical giant’s stock had closed 6% higher after its […]
Read More
Healthy Returns: Drugmakers release promising cancer drug data – and AstraZeneca wins big
Attendees walk through the lobby at the American Society of Clinical Oncology annual meeting in Chicago. Tim Boyle | Bloomberg | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! I’m back in New York City after spending the last weekend in […]
Read More
This up-and-coming cancer treatment could be a $25 billion market opportunity — it’s already a hotbed for M&A
Skynesher | E+ | Getty Images Big pharma is betting billions on an up-and-coming class of cancer treatments that some on Wall Street are calling a “massive opportunity.” It’s called targeted radiopharmaceutical therapy. It essentially delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule. RBC Capital Markets sees a $25 […]
Read More
A corner of the cancer therapy market is heating up—Here are the names investors need to know
There’s been a lot of attention lately on a corner of the oncology market called radiopharmaceuticals. The therapy seeks to destroy cancer cells by binding a radioactive particle to a targeted molecule and then dispatching it directly into the tumor. There are currently two products on the market from Novartis and a slew of clinical […]
Read More